Ring Sulfur In The Bicyclo Ring System Patents (Class 514/301)
-
Patent number: 11678659Abstract: The invention relates to a use, a method and a poison in which a thrombin inhibitor, a thrombin receptor antagonist, a factor Xa inhibitor, a PAI (plasminogen activator inhibitor), a P2Y12 ADP receptor antagonist or a GPIIb/IIIa receptor antagonist are used as rodenticide.Type: GrantFiled: June 11, 2015Date of Patent: June 20, 2023Inventor: Dietrich Gulba
-
Patent number: 11578290Abstract: The invention relates to surfactants of general formula (I) or general formula (II) or a mixture thereof, in which R represents a linear or branched alkyl, alkenyl, alkylaryl or alkenylaryl group having 5-25 C atoms and X+ represents a charge-balancing cation. The surfactants can be incorporated into detergents or cleaning agents, have excellent technological application properties and can be produced based on renewable raw materials.Type: GrantFiled: February 28, 2020Date of Patent: February 14, 2023Assignee: Henkel AG & Co. KGaAInventors: Christian Kropf, Anna Klemmer, Danuta Bedrunka, Regina Palkovits, Peter Hausoul, Carsten Stobbe
-
Patent number: 11571412Abstract: The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.Type: GrantFiled: November 18, 2019Date of Patent: February 7, 2023Assignee: Cumberland Pharmaceuticals Inc.Inventor: Leo Pavliv
-
Patent number: 11572370Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.Type: GrantFiled: January 8, 2019Date of Patent: February 7, 2023Assignee: BIOHAVEN THERAPEUTICS LTD.Inventors: Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
-
Patent number: 11566026Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.Type: GrantFiled: September 15, 2020Date of Patent: January 31, 2023Assignee: Incyte CorporationInventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
-
Patent number: 11466027Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.Type: GrantFiled: June 30, 2020Date of Patent: October 11, 2022Assignee: H. Lundbeck A/SInventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
-
Patent number: 11453660Abstract: The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.Type: GrantFiled: November 6, 2018Date of Patent: September 27, 2022Inventors: Guido Kurz, Juan Camacho Gómez
-
Patent number: 11186572Abstract: The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.Type: GrantFiled: December 1, 2017Date of Patent: November 30, 2021Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.Inventors: Jan Potempa, Sigrun Eick, Nadine Taudte, Jens-Ulrich Rahfeld, Mirko Buchholz, Hans-Ulrich Demuth
-
Patent number: 10995111Abstract: The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group comprising O, S, NH and N(allyl), T is hydrogen or a C1-10 substituted or unsubstituted alkyl group and * indicates where the moiety is connected to the remainder of the nucleotide or nucleoside).Type: GrantFiled: September 28, 2020Date of Patent: May 4, 2021Assignee: Illumina Cambridge LimitedInventors: Xiaohai Liu, John Milton, Silke Ruediger, Xiaolin Wu
-
Patent number: 10988483Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.Type: GrantFiled: May 18, 2018Date of Patent: April 27, 2021Assignee: NFlection Therapeutics, Inc.Inventors: John Kincaid, Matthew Duncton
-
Patent number: 10945999Abstract: The present disclosure provides a combination comprising: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable combination thereof. The combination may be used in the treatment and/or prevention of tuberculosis.Type: GrantFiled: April 7, 2017Date of Patent: March 16, 2021Assignees: QURETECH BIO AB, WASHINGTON UNIVERSITY IN SAINT LOUISInventors: Christina L. Stallings, Fredrik Almqvist, Kelly Flentie, James Arthur Dudley Good, Fritiof Ponten
-
Patent number: 10829496Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.Type: GrantFiled: May 10, 2018Date of Patent: November 10, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Saleem Ahmad, Ling Li, Lidet A. Negash, John Hynes
-
Patent number: 10793565Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.Type: GrantFiled: March 8, 2019Date of Patent: October 6, 2020Assignee: Incyte CorporationInventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
-
Patent number: 10676439Abstract: A pyridine compound having a SF5 group on position-3 and position-4 of a pyridine ring is provided.Type: GrantFiled: November 25, 2016Date of Patent: June 9, 2020Assignee: UBE INDUSTRIES, LTD.Inventors: Norio Shibata, Kohei Matsuzaki, Norimichi Saito
-
Patent number: 10647725Abstract: 2-Aminothiophene derivatives, uses of the same, and methods of making the same, are described.Type: GrantFiled: April 21, 2017Date of Patent: May 12, 2020Assignees: The University of Toledo, Colorado State University Research FoundationInventors: Steven Sucheck, Sandeep Thanna, Richard Slayden
-
Patent number: 10500205Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: December 9, 2016Date of Patent: December 10, 2019Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Patent number: 10471048Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.Type: GrantFiled: March 6, 2018Date of Patent: November 12, 2019Assignee: Cipla LimitedInventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
-
Patent number: 10398680Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.Type: GrantFiled: May 14, 2018Date of Patent: September 3, 2019Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENOInventors: Dean Burkin, Ryan Wuebbles
-
Patent number: 10130611Abstract: This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.Type: GrantFiled: May 7, 2012Date of Patent: November 20, 2018Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTERInventors: Sunghoon Kim, Jin Woo Choi, Jin Young Lee, Dae Gyu Kim, Gyoon Hee Han, Jee Sun Yang, Chul Ho Lee
-
Patent number: 10105353Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.Type: GrantFiled: October 3, 2013Date of Patent: October 23, 2018Assignee: IPCA LABORATORIES LIMITEDInventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki Moje
-
Patent number: 10064848Abstract: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.Type: GrantFiled: September 28, 2017Date of Patent: September 4, 2018Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
-
Patent number: 9938289Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: January 14, 2016Date of Patent: April 10, 2018Assignee: FBM THERAPEUTICS, LLCInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9937160Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.Type: GrantFiled: July 18, 2016Date of Patent: April 10, 2018Assignee: Cipla (UK) LimitedInventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
-
Patent number: 9913831Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.Type: GrantFiled: June 16, 2016Date of Patent: March 13, 2018Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang
-
Patent number: 9815848Abstract: This invention provides a new preparation method of Clopidogrel Hydrogen Sulfate spherical crystal form I, using single 2-butanol as solvent, controlling the concentration, addition way and addition speed of sulfuric acid used to salify to shorten the process time, thus separating out Clopidogrel Hydrogen Sulfate from solution system stably with spherality. And the Clopidogrel Hydrogen Sulfate obtained complies with the requirements of the follow-up process on residual solvent, bulk density and mobility.Type: GrantFiled: December 31, 2014Date of Patent: November 14, 2017Assignees: TIANJIN UNIVERSITY, SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTDInventors: Junbo Gong, Qi Wang, Qiuxiang Yin, Jingkang Wang, Xiaopeng Song, Baohong Hou, Liting Liao, Duanming Tan, Ziyuan Di
-
Patent number: 9778248Abstract: With a method for measurement of thrombocyte function, a solution is created, by which the sensitivity of individual thrombocytes can be measured with the least possible apparatus effort, with high throughput, by passing a liquid thrombocyte solution, in which the thrombocytes are present in isolated form, into a microfluidic chamber and brought into contact with at least one stimulant, wherein an electrical field directed transverse to the entry direction of the thrombocyte solution is applied to the chamber, and the movement path of the thrombocytes in the electrical field is observed and evaluated, in such a manner that thrombocytes having a movement path directed in the direction toward the minus pole of the electrical field are classified as non-activated thrombocytes, and thrombocytes having a movement path directed in the direction toward the plus pole of the electrical field are classified as activated thrombocytes.Type: GrantFiled: August 26, 2015Date of Patent: October 3, 2017Assignee: Leibniz—Institut fuer Analytische Wissenschaften—ISAS—e.V.Inventors: Jonathan West, Dirk Janasek, Albert Sickmann
-
Patent number: 9657014Abstract: The present invention relates to the use of compounds of general formula I wherein R?, R1, R2 and R3 are as defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, and for methods to treat a variety of neurodegenerative and neuropsychiatric diseases.Type: GrantFiled: May 20, 2015Date of Patent: May 23, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Jens-Uwe Peters, Juergen Wichmann
-
Patent number: 9562015Abstract: The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.Type: GrantFiled: November 16, 2012Date of Patent: February 7, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODYInventors: Uday B. Kompella, Ashish Thakur
-
Patent number: 9539246Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.Type: GrantFiled: August 29, 2012Date of Patent: January 10, 2017Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang
-
Patent number: 9512118Abstract: The present invention relates to a crystal of 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one useful as a prophylactic or therapeutic agent for schizophrenia and the like, which shows an X-ray powder diffraction pattern having characteristic peaks at interplaner spacings (d) of 13.59 plus or minus 0.2 and 6.76 plus or minus 0.2 Angstroms in powder X-ray diffraction.Type: GrantFiled: June 21, 2012Date of Patent: December 6, 2016Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventor: Katsuhiko Yamamoto
-
Patent number: 9504678Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.Type: GrantFiled: April 4, 2007Date of Patent: November 29, 2016Assignee: KG ACQUISITION LLCInventors: Mark A. Goldsmith, Elizabeth Vadas
-
Patent number: 9480680Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, m) of 100-500 nm, wherein the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc. The emulsion formulations and method of manufacturing significantly improves the stability of clopidogrel over other aqueous based formulations (such as cyclodextrin-based formulations and emulsion made using clopidogrel salt as the starting materials) with respect to chiral degradation, hydrolytic, and thermal degradation.Type: GrantFiled: February 6, 2014Date of Patent: November 1, 2016Inventor: Jingjun Huang
-
Patent number: 9402907Abstract: An object of the present invention is to provide a pharmaceutical composition containing compound I or a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient, which is favorably dissolved in the neutral region. The present invention relates to a pharmaceutical composition containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide or a pharmacologically acceptable salt thereof, or a solvate thereof, and (B) an acid or a salt thereof.Type: GrantFiled: August 9, 2012Date of Patent: August 2, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Koichi Ishidoh, Kazuhiro Matsuura
-
Patent number: 9403842Abstract: The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions.Type: GrantFiled: August 4, 2010Date of Patent: August 2, 2016Assignee: ratiopharm GmbHInventors: Sandra Brueck, Jana Paetz
-
Patent number: 9271972Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: GrantFiled: November 14, 2013Date of Patent: March 1, 2016Assignee: University of MassachusettsInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Patent number: 9248122Abstract: The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: GrantFiled: November 27, 2013Date of Patent: February 2, 2016Assignee: GRÜNENTHAL GMBHInventors: Sven Kühnert, Simon Lucas, Gregor Bahrenberg, Wolfgang Schröder
-
Patent number: 9193713Abstract: The present invention relates compounds of formula (I) wherein A and R1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.Type: GrantFiled: October 7, 2008Date of Patent: November 24, 2015Assignee: AbbVie Inc.Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Derek W. Nelson, Tongmei Li, Sridhar Peddi, Jennifer Frost, Teodozyj Kolasa, Bo Liu, Steven P. Latshaw, Xueqing Wang
-
Patent number: 9170126Abstract: An electronic device is described that includes a range indicator for conveying a range of travel until the electronic device ceases operation due to loss of power. In implementations, the electronic device includes a display device, a memory operable to store one or more modules, and at least one processor coupled to the display device and the memory. The processor is operable to execute the one or more modules to cause display of navigation information at the display device. The navigation information includes a map graphic representing an area an aircraft is traversing. The navigation information also includes an end of use situation that represents a range of travel for the aircraft until the electronic device ceases operation due to a loss of power.Type: GrantFiled: August 22, 2013Date of Patent: October 27, 2015Assignee: Garmin International, Inc.Inventors: Christopher E. P. Schulte, Douglas E. Leeper, Jr.
-
Patent number: 9138392Abstract: Provided is a nontherapeutic cosmetic process for depigmenting, lightening and/or whitening keratin materials applying an effective amount of at least one compound of formula (I): or a tautomer thereof of formula (I?): to a keratin material, where the structural variables are as defined herein.Type: GrantFiled: December 8, 2011Date of Patent: September 22, 2015Assignee: L'OREALInventor: Xavier Marat
-
Patent number: 9133186Abstract: Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein a group represented by the formula: is a group represented by the formula: R1 is each independently halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like; m is an integer of 0 to 3; R2 is hydrogen, or substituted or unsubstituted alkyl; X is —O—; and Y is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.Type: GrantFiled: September 8, 2011Date of Patent: September 15, 2015Assignee: Shionogi & Co., Ltd.Inventors: Keisuke Tonogaki, Akira Ino, Eiichi Kojima, Manabu Katou, Masafumi Iwatsu, Nobuyuki Tanaka, Masahiko Fujioka
-
Publication number: 20150148308Abstract: A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, strobilurins, phenylamides, rice blast controlling compounds, rice sheath blight disease controlling compounds, and other fungicidal compounds. The composition has an excellent controlling effect against harmful arthropods.Type: ApplicationFiled: June 5, 2013Publication date: May 28, 2015Applicant: Sumitomo Chemical Company, LimitedInventors: Tatsuya Suzuki, Atsushi Iwata, Yoshihiko Nokura
-
Patent number: 9040707Abstract: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.Type: GrantFiled: December 16, 2010Date of Patent: May 26, 2015Assignee: Janssen Pharmaceutica NVInventors: Gregor James MacDonald, Andrés Avelino Trabanco-Suárez, Susana Conde-Ceide, Gary John Tresadern, José Manuel Bartolomé-Nebreda, Joaquin Pastor-Fernández
-
Publication number: 20150141423Abstract: Disclosed are pesticidally active pyridyl- and pyrimidyl-substituted thiazole derivatives, processes for their preparation, compositions comprising those compounds, and their use for controlling insects.Type: ApplicationFiled: June 4, 2013Publication date: May 21, 2015Applicant: Syngenta Participations AGInventors: Ruifang Chen, Laura Quaranta, Andrew Edmunds, Andre Jeanguenat, Aurelien Bigot, Sebastian Rendler, Roger Graham Hall, Long Lu, Peter Renold
-
Patent number: 9034896Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene) Heterocyclopenta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: GrantFiled: April 21, 2014Date of Patent: May 19, 2015Assignee: Allergan, Inc.Inventors: Santosh C. Sinha, Liming Wang, Ken Chow, Mohammed I. Dibas, Michael E. Garst
-
Patent number: 9029378Abstract: Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).Type: GrantFiled: July 25, 2012Date of Patent: May 12, 2015Assignee: Gruenenthal GmbHInventors: Robert Frank, Thomas Christoph, Bernhard Lesch, Jeewoo Lee
-
Patent number: 9029390Abstract: The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.Type: GrantFiled: June 15, 2009Date of Patent: May 12, 2015Assignee: CLL PharmaInventors: Thierry Breul, Claude Laruelle
-
Publication number: 20150126529Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: January 16, 2015Publication date: May 7, 2015Inventors: Upender Velaparthi, Peiying Liu
-
Publication number: 20150126545Abstract: A composition comprises a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea, in a mixture comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. The composition is suitable for dilution with an IV solution for administration to a subject in need thereof for treatment of a cancer.Type: ApplicationFiled: December 14, 2012Publication date: May 7, 2015Applicant: AbbVie Inc.Inventors: Yi Shi, Josh M. Lipari, Brian E. Padden, Lloyd S. Dias, Julie K. Spence
-
Patent number: 9018207Abstract: The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.Type: GrantFiled: March 28, 2014Date of Patent: April 28, 2015Assignee: Spinifex Pharmaceuticals Pty LtdInventors: Maree Therese Smith, Bruce Douglas Wyse
-
Patent number: 9012641Abstract: Salts of prasugrel were prepared including, for example, crystalline forms of prasugrel hydro bromide. These salts are useful, for example, in medicaments that inhibit the aggregation of platelets.Type: GrantFiled: July 22, 2014Date of Patent: April 21, 2015Assignee: Teva Pharmaceuticals Industries Ltd.Inventors: Mihaela Tuksar, Tomislav Biljan, Miroslav Zegarac